AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

Recursion Pharmaceuticals teamed up with AI biotech Exscientia last year in a deal worth almost $700 million. The matchup marked the biggest life sciences AI merger to date and comes amid a “surge in AI partnerships and acquisitions in the past five years [that] signals the opportunities the technology offers to life sciences companies,” according to an EY report.